The goal of this observational study is to better understand how the immune system and certain tumor markers are linked to treatment response in patients with advanced non-small cell lung cancer (NSCLC) who receive immunochemotherapy.
The investigators aim to answer the following questions:
* Can the investigators successfully analyze immune markers and gene activity from small tumor samples (biopsies)? * Are these markers connected to how well patients respond to immunochemotherapy and how their disease progresses?
What will participants do?
* Provide tumor tissue samples (biopsies) at key points: before treatment, about 6 weeks after starting immunochemotherapy, and if the cancer grows or treatment changes. * Allow their tumor samples to be analyzed in the lab using advanced techniques to measure immune and genetic markers. * Share clinical information (such as treatment response and disease progression) so investigators can study how it relates to these markers.
This study does not test a new drug or treatment.
Written informed consent of the patient
Consent of participation in the national Network for Genomic Medicine in Lung Cancer (nNGM)
Advanced lung cancer with non-curative treatment option (NSCLC)
No targetable driver mutation detected, defined as no targetable drive mutation in ALK, EGFR, BRAF, HER2, MET, NTRK, RET, ROS1
Any condition representing an unjustified risk for obtaining an additional biopsy sample (if needed) in the view of the investigator
Incapability of understanding the purpose and possible consequences of the trial
Substance abuse, medical, psychological or social conditions that may interfere with the subject's cooperation with the requirements of the trial or evaluation of the study results
Technische Universität Dresden
Lead sponsor
Deutsche Krebshilfe e.V., Bonn (Germany)
Collaborator
Universitätsklinikum Köln
Collaborator